UBS expects 'no material impact' on DLF from Kejriwal's accusations
MUMBAI (Reuters) - India's biggest property developer DLF was likely to suffer no material impact from accusations by Arvind Kejriwal and his group India Against Corruption (IAC) of improper dealings, and the issue had been largely priced in to the stock, UBS said.
Activists from IAC on Friday accused DLF arranging favourable loans and real estate transactions to Robert Vadra, the son-in-law of ruling Congress party chief Sonia Gandhi.
The anti-graft group also accused DLF on Tuesday of receiving undue favours from the Haryana government.
DLF shares slumped 11 percent by Wednesday's close, wiping $920 million off its market value. DLF and Vadra have denied the accusations. Harayana state officials also denied the allegations in local media.
"With the stock down 11 percent on the back of this news flow, and our expectation of no material impact on DLF's business - we believe concerns are largely priced in," UBS said in a note dated on Wednesday.
UBS added the allegations against DLF would be difficult to investigate given the issues were "politically motivated" and had happened three to four years ago. The linkage of politicians with real estate developers had been a common concern in the sector, it added.
Kejriwal, who announced both sets of allegations, is setting up an anti-corruption political party.
UBS maintained its 'buy' rating on DLF, saying the stock offered "an attractive risk-reward opportunity" given potential interest rate cuts by the RBI and possible early debt reductions following asset sales.
Goldman Sachs, however, took a more negative view on DLF's outlook, downgrading the stock to 'neutral' from 'buy'.
Goldman warned slower regulatory approvals could result in fewer project launches, while cutting its pre-sale estimates for India's largest property developer, in a note dated on Thursday. It did not discuss the IAC allegations.
DLF shares were up 1.4 percent as of 11:30 a.m. on Thursday, outperforming a 0.2 percent fall in the Nifty.
(Reporting by Rafael Nam and Abhishek Vishnoi; Editing by Richard Pullin)
- Tweet this
- Share this
- Digg this
- India withdraws regulator's power to cap non-essential drug prices
- India's Mars mission a step closer to success with engine test
- Apple sells more than 10 million new iPhones in first three days |
- U.S. Treasury moves against tax-avoidance 'inversion' deals
- PM Modi to get rock star reception in New York
India has withdrawn the drug pricing authority's powers that allowed it to fix the prices of medicines not deemed essential, after its decision to impose price caps on more than 100 drugs in July triggered industry protests. Article
India has no plans to increase food handouts - Food Minister Ram Vilas Paswan. Full Article